Baxter International Inc Stock News

Baxter (NYSE:BAX) is scheduled to announce Q4 earnings results on Thursday, February 17th, before market open.The consensus EPS Estimate is $1.03 and the consensus Revenue Estimate…

Kaizer Chiefs star Nkosingiphile Ngcobo is dealing with a slight setback before he looks forward to a dream opportunity.

BAX vs. SYK: Which Stock Is the Better Value Option?

Baxter (NYSE:BAX) declares $0.28/share quarterly dividend, in line with previous.Forward yield 1.31%Payable April 1; for shareholders of record Feb. 25; ex-div Feb.

Baxter's (BAX) fourth-quarter results are likely to reflect growth in its Acute Therapies business.

If any investor has stood the test of time, it is Warren Buffett, and with good reason.

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at Citis 2022 Virtual Healthcare Conference on Wednesday, February 23, 2022. Jay Saccaro, Baxters chief financial officer, is scheduled to present at 1:15 p.m. Eastern Time. The live webcast of Baxters presentation can be accessed at www.baxter.com and will be available for replay through February 22, 2023. About Baxter Every day, millions of patients and caregivers rely on Baxters

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at Citi's 2022 Virtual Healthcare Conference on Wednesday, February 23, 2022. Jay Saccaro,

Investors are optimistic about Baxter's (BAX) strong product portfolio.

Pune, India, Feb. 09, 2022 (GLOBE NEWSWIRE) -- The Bone Void Fillers Market to Generate USD 3.90 Billion by 2027 Owing to Increasing Prevalence of Bone-Associated Disease, with stunning 5.4% CAGR by 2021-2027. Adoption of Technologically Advanced Products Globally to Surge Demand. Biocomposites Receiving CE Mark from The European Union to Create Exponential Growth Opportunities Industry Development: In September 2018, US-based Baxter International Inc. obtained clearance from U.S. Food and Drug Administration or FDA for ALTAPORE Bioactive Bone Graft. This medical invention is a next generation osteoconductive and bioactive substitute of bone grafts. In 2019, Medtronic plc introduced Grafton demineralized bone matrix (DBM) bone grafting product to the Japanese market. Grafton DBM is the first of its kind demineralized bone matrix product that is made available in Japan. Get Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/bone-void-fillers-market-101015 Scope Of The Report: Historical Years: 2016-2018 Base Year: 2019 Forecast Period: 2020–2027 Drivers and Restraints: Rising demand, coupled with increased awareness about advanced technology enabled orthopedic surgeries in India and China in the recent years, is expected to boost the demand for bone void fillers.

Baxter (BAX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Baxter International Inc. with ticker code (BAX) now have 15 analysts in total covering the stock. The consensus rating is ''Buy''. The target price ranges between 110 and 88 calculating the mean target price we have 97.8. Now with the previous closing price of 86.1 this would imply there is a potential upside of 13.6%. The 50 day MA is 83.73 and the 200 day MA is 81.37. The company has a market cap of $43,415m. You can visit the company''s website by visiting: https://www.baxter.com [stock_market_widget type="chart" symbol="BAX" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] The potential market cap would be $49,315m based on the market concensus. Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

The Medical Products companies' Q4 results are likely to reflect base business recovery. Let's see how BAX, HSIC, and XRAY are poised ahead of their earnings releases.

Here is how Baxter International (BAX) and Gamida Cell (GMDA) have performed compared to their sector so far this year.